Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pulmonary suffusion may also be useful in avoiding later use of drugs by vein that demonstrate no

Trial Details

NCT ID
NCT03965234
Phase
PHASE1 / PHASE2
Sponsor
Roswell Park Cancer Institute
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Cisplatin
  • Isolated Chemotherapeutic Lung Perfusion
  • Metastasectomy
Locations (sample)
  • Buffalo, New York, United States|42.88645,-78.87837

Key Eligibility Criteria

  • Tumors metastatic to the lungs that are the focus of this protocol specifically:
  • Soft tissue sarcoma
  • Osteosarcoma
  • Colorectal carcinoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →